Moderna, Inc outlined it’s next phase of growth strategy at 2026 Analyst Day, highlighting how more than a decade of investment in the company’s mRNA platform has enabled the development of multiple modalities of mRNA medicines, each with the potential to create durable franchises.

The company also provided updates on commercial growth, oncology pipeline progress, manufacturing readiness, and mid-term financial objectives.

What is Moderna’s business strategy?

Moderna’s strategy rests on an integrated mRNA platform that combines mRNA science, delivery technologies, and manufacturing capabilities.¹ By developing modalities that share underlying technologies and processes, the company is aiming to improve development efficiency and capital productivity while expanding the range of potential applications for mRNA medicines.¹ Moderna has developed three established modalities spanning infectious disease vaccines, individualized cancer treatments, and rare genetic liver diseases, with intismeran advancing toward potential commercialization following positive Phase III results in adjuvant melanoma, subject to regulatory approval.²

The company is identifying commercial growth opportunities for 2027 and beyond including seasonal influenza, where Moderna is preparing for a broader commercial launch during the 2027-2028 respiratory season.¹ In Europe, the company now has four approved respiratory vaccines in the European Union and is positioned for additional growth as a competitor’s Covid-19 vaccine contract expires. Long-term strategic partnerships in the United Kingdom, Canada, and Australia provide recurring revenue and support domestic manufacturing, while new agreements in Mexico and Taiwan are set to expand opportunities in Latin America and Asia-Pacific.¹

Stéphane Bancel, chief executive officer of Moderna, frames the event as a milestone in the company’s decade-long platform-building effort. “We founded Moderna on the belief that mRNA could transform medicine, and over the past decade we have built a powerful platform to realize that vision,” Bancel says. “Our strategy is to create new modalities that can generate families of medicines and build durable franchises. We have demonstrated the potential of this approach in infectious diseases and are now advancing intismeran toward potential commercialization. Artificial intelligence and automation are accelerating what our platform can achieve, positioning Moderna to bring the next generation of mRNA medicines to patients around the world.”

How is Moderna building out its manufacturing network?

Manufacturing is a core component of Moderna’s integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships, and the potential launch of individualized cancer therapies. Manufacturing operations across the United States, United Kingdom, Canada, and Australia provide regional supply capabilities, geographic diversification, and flexibility for future product launches.¹ In infectious diseases, the company continues to focus on manufacturing efficiency, productivity, and margin expansion, with the mRNA platform enabling rapid vaccine design and production and opportunities to shorten manufacturing timelines compared with traditional vaccine technologies.

What is the latest on Moderna’s oncology pipeline?

In collaboration with Merck, the Phase III Interpath-001 study of intismeran autogene (mRNA-4157/V940) in resected high-risk melanoma met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival.² Intismeran in combination with Keytruda (pembrolizumab) demonstrated a 42% reduction in the risk of recurrence or death and a 38% reduction in the risk of distant metastasis or death compared with Keytruda alone.

The safety profile of intismeran in combination with Keytruda was consistent with the known profiles of the individual therapies, with the most common adverse events in the combination arm including fever, injection-site pain, and fatigue, which were generally low-grade, transient, and manageable with standard supportive care. The Phase III results were published in The New England Journal of Medicine, and the companies continue to advance clinical development across multiple tumor types and treatment settings.²

Beyond intismeran, Moderna is advancing a portfolio of off-the-shelf cancer antigen therapies, including mRNA-4359 in a Phase II clinical trial in melanoma and non-small cell lung cancer, along with mRNA-4106, mRNA-4200, and mRNA-4194 in early clinical development.¹.

What did Moderna say about its financial outlook?

Moderna expects 2026 revenue growth of 15% to 25%, compared with its original outlook of up to 10%, and is on track to achieve approximately 10 percentage points of gross margin expansion in 2026, excluding the litigation settlement charge.¹ The company has accelerated cost reductions, bringing forward its previously announced 2027 cash cost framework into 2026, and now expects approximately $4 billion in cash costs in 2027 and annual cash costs of approximately $4 billion to $4.5 billion from 2027 through 2030, primarily driven by increased investment in oncology.

Formal 2027 financial guidance is expected during Moderna’s fourth-quarter 2026 earnings call, which will give investors their next look at how the growth targets and oncology investment laid out at this Analyst Day translate into the company’s near-term numbers.¹

Sources

1. Moderna Outlines Next Phase of Growth at Analyst Day Moderna November 12, 2026, https://feeds.issuerdirect.com/news-release.html?newsid=8697104470082996&symbol=MRNA
2. Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma The New England Journal of Medicine November 11, 2026, https://www.nejm.org/doi/full/10.1056/NEJMoa2609762?query=featured_home&referrer=https%3A%2F%2Ffeeds.issuerdirect.com%2F